Simple Urine Test Could Illuminate Hidden Tumors for Early Cancer Diagnosis

Many solid tumors go undetected until advanced stages, drastically reducing survival rates. To address this global challenge, researchers have developed a groundbreaking approach that enables the detection of more than 30 types of Stage 1 cancers through a simple, at-home urine test, marking a potential revolution in cancer screening and diagnosis.

Researchers from Carnegie Mellon University’s College of Engineering (Pittsburgh, PA, USA), in collaboration with private industry partners, are leading this effort through a project funded by the U.S. Advanced Research Projects Agency for Health (ARPA-H) under the POSEIDON program. The project combines advances in synthetic biology, nanotechnology, and biosensing to create an orally administered pill and a compact, user-friendly screening device. Together, they aim to provide accurate, affordable, and accessible early cancer detection.

The pill contains specially engineered tumor-targeting biosensors that detect hallmark features of cancer, such as low oxygen levels, high acidity, and elevated lactate concentrations. Once these sensors identify tumor conditions, they release synthetic RNA reporters, which are later excreted in the urine. The accompanying device, integrated with CRISPR-Cas-based biosensors, analyzes these RNA reporters to identify both the presence and the tissue of origin of the cancer, transmitting the data wirelessly to a smartphone app for immediate interpretation.

The multi-party team aims to move this multi-cancer detection kit into human trials. The goal is to make the test affordable, costing less than USD 100, while maintaining high accuracy and clinical utility. This approach could drastically reduce healthcare burdens by enabling proactive screening outside clinical settings.

If successful, this technology will transform cancer care by shifting diagnostics from reactive to preventive. By allowing users to test themselves from home and receive instant results, the system could detect tumors long before symptoms appear, saving millions of lives through earlier intervention. Beyond oncology, the platform’s synthetic biology framework could be adapted for other diseases that rely on early molecular detection.

“Our dual-function approach is designed to provide an unprecedented level of precision, effectively illuminating hidden tumors from within the body, which then signals the presence of disease through a simple urine test,” said Rebecca Taylor, principal investigator of the project. “This is a scientific leap forward that we believe will profoundly change how we approach early cancer diagnostics.”

Related Links:
CMU College of Engineering